BusinessCidara Therapeutics Announces Pricing of Public Offering of Common StockBy Nasdaq OMXOct 7, 2016, 1:00 PM UTC
BusinessCell Design Labs Announces Peer-Reviewed Publication Validating Ability to Program Immune Cells to Treat Cancer and Autoimmune DiseaseBy Nasdaq OMXSep 29, 2016, 4:00 PM UTC
BusinessPeregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXSep 27, 2016, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 CongressBy Nasdaq OMXSep 21, 2016, 12:05 PM UTC
BusinessCidara Therapeutics to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-OncologyBy Nasdaq OMXSep 20, 2016, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXSep 8, 2016, 8:05 PM UTC
BusinessVCANBIO USA and VCANBIO Center for Translational Biotechnology Launch in the United StatesBy Nasdaq OMXSep 8, 2016, 12:01 PM UTC
